| Literature DB >> 28732687 |
Filip Rázga1, Veronika Némethová2.
Abstract
Despite the massive global spend on biology-driven drug discovery, tackling the issue of side effects and adverse events resulting from drug promiscuity represents a persistent challenge. Although delivering authentic medical innovations today is more complex than ever, minimization of off-target effects should be a priority.Keywords: drug design; off-targets; selective intervention; side effects; target recognition
Mesh：
Year: 2017 PMID： 28732687 DOI： 10.1016/j.molmed.2017.06.007
Source DB: PubMed Journal: Trends Mol Med ISSN： 1471-4914 Impact factor: 11.951